A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 37-46

  Colombo, Giorgio L ^a,b   Gaeta, Giovanni B ^c   Viganò, Mauro ^d   di Matteo, Sergio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Adefovir; Chronic hepatitis B; Cost effectiveness; Entecavir; Lamivudine; Markov model; Pegylated interferon; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; BONE DENSITOMETRY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS B; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NATIONAL HEALTH SERVICE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SEROCONVERSION;

EID: 79952977384     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S16655     Document Type: Review

References (59)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2): 227-242.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14): 1486-1500.
3. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009; 18(11):1655-1666.
4. Chang TT, Gish RG, de Man R, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
5. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23):2442-2455.
6. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010 [Epub ahead of print].
7. Giannini EG, Torre F, Basso M, et al; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy. J Clin Gastroenterol. 2009;43(10):1001-1007.
8. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol. 2003;39(6):1036-1041.
9. Idris BI, Brosa M, Richardus JH, et al. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol. 2008;20(4):320-326.
10. Heathcote JE, Gane EJ, de Man A, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. Hepatology. 2008;48 Suppl 4:309A.
11. Heathcote JE, Gane EJ, de Man A, et al. Three years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. Hepatology. 2009;50 Suppl 4:533A.
12. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
13. Lai CL, Yuen MF. Chronic hepatitis B: new goals, new treatment. N Engl J Med. 2008;359(23):2488-2491.
14. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808-816.
15. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576-2588.
16. Lai CL, Gane E, Hsu CW, et al. Two-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine [Abstract]. Hepatology. 2006;44 Suppl 1:222A.
17. Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis [Abstract]. Hepatology. 2008;48 Suppl 4:370A.
18. Marcellin P, Buti M, Krastev Z, et al. Three years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. Hepatology. 2009;50 Suppl 4:532A.
19. Di Marco V, Marzano A, Lampertico P, et al. Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883-891.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743-1751.
21. Senturk H, Lurie Y, Gadano A, et al. ETV re-treatment of nucleosidenaive HBeAg(-) [Abstract]. J Hepatol. 2007;46 Suppl 1: S197.
22. Shouval D, Lai CL, Chang TT, et al. Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901. Hepatology. 2008;48 Suppl 4:722A.
23. Lai CL, Shouval D, Lok AS, et al; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-1020.
24. Erratum in: N Engl J Med. 2006;354(17):1863.
25. Shouval D, Akarca US, Hatzis G, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). J Hepatol. 2006;44 Suppl 2:S21-S22.
26. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB). Hepatology. 2009;50 Suppl 4:533A.
27. Snow-Lampart A, Chappell BJ, Curtis M, et al. HBeAg+ and HBeAghepatitis B patients treated with tenofovir df showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology. 2009;50 Suppl 4:523A.
28. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125(6):1714-1722.
29. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48(3):750-758.
30. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-1514.
31. Liaw YF, Gane E, Leung N, et al. GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486-495.
32. Fontana RJ. Hepatitis B: a "GLOBAL" health challenge. Gastroenterology. 2009;136(2):389-392.
33. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135(2):459-467.
34. Janssen HL, van Zonneveld M, Senturk H, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123-129.
35. Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a HBeAg- Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12): 1206-1217.
36. Marcellin P, Bonino F, Lau GK, et al. Peginterferon alfa-2a in HBeAgnegative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169-2179:e1-e4.
37. Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30(4):512-520.
38. Marcellin P, Chang TT, Lim S, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients increasing serologic, virologic and biochemical response over time. Hepatology. 2004;40(1) Suppl 4:655A.
39. Leung N, Peng CY, Sollano J, et al. Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviralnaive HBeAg+ adults with high HBVDNA: Week 96 results (E.A.R.L.Y. study). J Hepatol. 2008;48:S373-S374.
40. Yao G, Chen CW, Lu WL, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493.
41. Han S, Chang T-T, Chao YC, et al. Four-year entecavir treatment in nucleosidenaïve HBeAg(+) patients: results from studies ETV-022 And -901. Hepatology. 2007;46(4) Suppl 1:654A.
42. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447-454.
43. Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008;2(1):102-110.
44. Drummond MF, Schulpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
45. Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther. 2007;26(3):383-391.
46. Sullivan SD, Craxi A, Alberti A, et al. Rapporto costo efficacia della terapia peginterferone alfa-2a+ribavirina in confronto a interferone alfa-2b+ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. PharmacoEconomics. 2004;6:105-114.
47. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005;142(10):821-831.
48. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 2000;20(4):451-467.
49. Health Ministry. National Tariff Nomenclature. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale. Ministero della Salute; 2010.
50. Conferenza delle Regioni e delle Province autonome 1O/014/CR10a/C7. DRG 206, Tariffa Unica Convenzionale (TUC) per le prestazioni di assistenza ospedaliera, regole e tariffe valide per l'anno 2009secondo CMS-DRG Versione 24. DRG 206; DRG 202; DRG 199; DRG 480; Roma 2010.
51. Tumiatti C, Bezzon C, Guasti F, Franchin M. Il costo del trapianto d'organo: risultati di uno studio condotto presso l'Azienda Ospedaliera di Padova. Azienda Ospedaliera di Padova. 1999:39. valori attualizzati al 2009.
52. Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996; 89.7: visita specialistica, prima visita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe.
53. Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996;90.16.3: creatinina, 90.24.3 fosfato organico. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe.
54. The National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. Second ed. 2008. http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf. Accessed July 14, 2010.
55. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51(4):640-646.
56. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. September 3, 2010. [Epub ahead of print].
57. Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari. PharmacoEconomics - Italian Research Articles. 2009;11: 83-93.
58. Lucioni C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico?. PharmacoEconomics - Italian Research Articles. 2004;(3):121-130.
59. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics - Italian Research Articles. 2003;5:53-67.